Addressing Challenges to Alternative Payment Models for New
Alzheimer's Disease Therapies for US Commercial Payers

J 2022

Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers

HLÁVKA, Jakub; Tara A. LAVELLE; Peter J. NEUMANN a Pei-Jung LIN

Základní údaje

Originální název

Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers

Autoři

HLÁVKA, Jakub; Tara A. LAVELLE; Peter J. NEUMANN a Pei-Jung LIN

Vydání

PHARMACOECONOMICS, NORTHCOTE, ADIS INT LTD, 2022, 1170-7690

Další údaje

Typ výsledku

Článek v odborném periodiku

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 4.400

Označené pro přenos do RIV

DOI

https://doi.org/10.1007/s40273-022-01150-w

UT WoS

000794076000002

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2025 09:45, Mgr. Alžběta Karolyiová

Anotace

V originále

Commercial payers that ultimately decide to cover aducanumab or other Alzheimer's disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer's disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer's disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer's disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer's disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.

Citovat

HLÁVKA, Jakub; Tara A. LAVELLE; Peter J. NEUMANN a Pei-Jung LIN. Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers. PHARMACOECONOMICS. NORTHCOTE: ADIS INT LTD, 2022, roč. 40, č. 7, s. 647-652. ISSN 1170-7690. Dostupné z: https://doi.org/10.1007/s40273-022-01150-w.

@article{2472546,
   author = {Hlávka, Jakub and Lavelle, Tara A. and Neumann, Peter J. and Lin, PeiandJung},
   article_location = {NORTHCOTE},
   article_number = {7},
   doi = {https://doi.org/10.1007/s40273-022-01150-w},
   issn = {1170-7690},
   journal = {PHARMACOECONOMICS},
   title = {Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers},
   volume = {40},
   year = {2022}
}

TY  - JOUR
ID  - 2472546
AU  - Hlávka, Jakub - Lavelle, Tara A. - Neumann, Peter J. - Lin, Pei-Jung
PY  - 2022
TI  - Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers
JF  - PHARMACOECONOMICS
VL  - 40
IS  - 7
SP  - 647-652
EP  - 647-652
PB  - ADIS INT LTD
SN  - 11707690
N2  - Commercial payers that ultimately decide to cover aducanumab or other Alzheimer's disease therapies may require innovative payment tools to minimize their financial risk given the uncertain benefits and high cost of such treatments. Drawing on the published evidence, we propose two different types of payment models applicable to disease-modifying therapies in Alzheimer's disease, and suggest four strategies to overcome challenges in their implementation. Such strategies range from developing best practices for outcome measurement in Alzheimer's disease, investing in infrastructure to collect real-world data, increasing representativeness of registry data in Alzheimer's disease, and integrating the diagnostic, treatment, and payment landscape. These important steps could make access to emerging therapies in Alzheimer's disease more sustainable in the long term, and could serve as a blueprint for better access to novel therapies in other indications in the future.
ER  -

HLÁVKA, Jakub; Tara A. LAVELLE; Peter J. NEUMANN a Pei-Jung LIN. Addressing Challenges to Alternative Payment Models for New Alzheimer's Disease Therapies for US Commercial Payers. \textit{PHARMACOECONOMICS}. NORTHCOTE: ADIS INT LTD, 2022, roč.~40, č.~7, s.~647-652. ISSN~1170-7690. Dostupné z: https://doi.org/10.1007/s40273-022-01150-w.

Přehled o publikaci